- Some clinical trials require larger amounts of plasma and white blood cells than can be
collected through simple blood donations. Apheresis is a procedure used to collect parts of
the blood for study and return the rest of the blood to the donor. Healthy volunteers who
provide plasma and white blood cells for study may need to give multiple donations.
Researchers want to use apheresis to collect plasma and white blood cells from healthy
volunteers in Mali.
- To collect plasma and white blood cells from healthy volunteers in Mali.
- Healthy volunteers between 18 and 55 years of age.
- Volunteers must be in National Institute of Allergy and Infectious Diseases clinical
- Participants will be screened with a physical exam and medical history. They will also
provide basic blood and urine samples.
- Participants will have apheresis to collect plasma and white blood cells for study.
Before each collection, they will provide a small blood sample for testing. They will be
monitored during and after donation to prevent side effects.
- Under this protocol, participants may have apheresis up to six times per year.
- No treatment will be provided as part of this protocol.
To carry out in vitro research procedures on plasma or leukocyte components of whole blood,
it is often necessary to obtain larger quantities of plasma or leukocytes than can be safely
obtained by simple phlebotomy. These components can be easily and safely obtained using a
well-established standard apheresis procedure that is in common use at the National
Institutes of Health Apheresis Unit. This protocol describes the implementation of the same
apheresis procedure at the National Blood Transfusion Center in Bamako, Mali. This is not a
research protocol per se, but rather an adjunct protocol which allows healthy donors 18-55
years of age to undergo apheresis. Subjects must already be enrolled in another protocol
which has been approved by the National Institute of Allergy and Infectious Diseases
Institutional Review Board and the Faculty of Medicine, Pharmacy, and Odonto-Stomatology
|Condition or disease
|First Submitted Date||January 13, 2012|
|Last Update Posted Date||February 22, 2018|
|Start Date||December 20, 2011|
|Completion Date||July 28, 2016|
|Primary Completion Date||N/A|
|Results First Submitted Date||N/A|
|Received Results Disposit Date||N/A|
Current Primary Outcome Measures
Original Primary Outcome Measures
Current Secondary Outcome Measures
Original Secondary Outcome Measures
|Brief Title||Apheresis to Obtain Plasma and White Blood Cells in Malies|
|Official Title||Apheresis to Obtain Plasma and Leukocytes in Mali for In Vitro Studies|
|Target Follow-Up Duration|| N/A|
|Completion Date||July 28, 2016|
- INCLUSION CRITERIA:|
Individuals 18-55 years of age are eligible to enter the study if they:
- Are enrolled on another NIAID/FMPOS-approved protocol.
- Weigh greater than or equal to 50 kg.
- Agree to have blood specimens stored for future studies.
- Agree to undergo genetic testing.
- Agree to undergo HIV, hepatitis B, and hepatitis C virus testing.
The following criteria are exclusionary:
- Positive at screening for HIV, hepatitis B, and/or hepatitis C.
- Cardiovascular instability (blood pressure <90/50 or >180/100; pulse <40 or >110.
- Inadequate peripheral venous access.
- Anemia (hemoglobin <11 g/dL).
- Current use of corticosteroids or other immunosuppressants.
- Underlying heart disease, lung disease, bleeding disorder, or other conditions that,
in the judgment of the investigator, contraindicates apheresis.
- Temperature greater than or equal to 37.5 degree C or other clinical evidence of an
- Currently pregnant or breastfeeding.
|Age||18 Years to 55 Years|
|Accepts Healthy Volunteers||No|
|Listed Location Countries
|Other Study ID Numbers
|Has Data Monitoring Committee||No|
|U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Device Product Not Approved or Cleared by U.S. FDA: No
|IPD Sharing Statement
|Responsible Party||, |
Peter D Crompton, M.D.
National Institute of Allergy and Infectious Diseases (NIAID)